561Wire StoriesCubic Technology Launched to Provide Easier Rail Journeys for Queensland Commuters
Cubic Transportation Systems launches the first credit card and smart device-compatible gates on Queensland’s Heavy Rail Network, giving more payment options to...
- 559Wire Stories
Kite Realty Group Trust to Present at NAREIT’s REITweek: 2022 Investor Conference
INDIANAPOLIS, June 03, 2022 (GLOBE NEWSWIRE) — Kite Realty Group Trust (NYSE: KRG) announced today that it will present at Nareit’s REITweek:...
- 493Wire Stories
Global Commercial Vehicle Surround View System Markets, 2021-2030: Revenue, Trends, Growth Opportunities, Competition, End Cases – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Commercial Vehicle Surround View System Market – Revenue, Trends, Growth Opportunities, Competition, COVID-19 Strategies, Regional Analysis and Future Outlook to...
- 525Wire Stories
Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year...
- 528Wire Stories
Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer
Data from a phase 1/2 trial in patients with several subtypes of HER3 expressing metastatic breast cancer featured as oral presentation at...
- 519Wire Stories
Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer
Data from a phase 1/2 trial in patients with several subtypes of HER3 expressing metastatic breast cancer featured as oral presentation at...
- 551Wire Stories
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year...
- 617Wire Stories
OliX Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OLX101A in Patients with Hypertrophic Scars
SUWON, South Korea–(BUSINESS WIRE)–#ClinicalTrial—OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the completion of patient enrollment in...
- 660News
Apical Wins Five Awards at the Sustainable Business Awards Indonesia 2020/2021
-Apical Wins Top Honours in ‘Land Use and Biodiversity’ and ‘Stakeholder Management’- JAKARTA, INDONESIA – Media OutReach – 3 June 2022 –...
- 499News
XLD Launches xSpend in Malaysia, allows users to spend Crypto Assets for Utilities
KUALA LUMPUR, MALAYSIA – Media OutReach – 3 June 2022 – XLD Finance, a stablecoin-based ecosystem that drives financial inclusion through real-world...
